Boom.. this is the news longs are waiting for..drones drones drones $$
Sentiment: Strong Buy
10/22/2015 Bank of America Reiterated Rating Buy $290.00 View Rating Details Tweet This Rating Share This Rating on StockTwits
10/21/2015 Nomura Reiterated Rating Buy $290.00 View Rating Details Tweet This Rating Share This Rating on StockTwits
10/20/2015 RBC Capital Reiterated Rating Outperform $250.00 - $231.00 View Rating Details Tweet This Rating Share This Rating on StockTwits
10/20/2015 Deutsche Bank Reiterated Rating Hold $220.00 - $204.00
AXON and AVXL these Alzheimer drugs are all becoming scams. With 5 to 7 people in their offices makes you wonder.
bought at 27 out at 31 and thanks.
thats why own
just got in, Co will announce Double Survival Rate and VBLT Will Fly- Chardin Nails it.
Esperion Plunges on FDA Advice for Cardiovascular Study
Zacks By Zacks Equity Research
10 hours ago
However, investors seem to be disappointed by the FDA’s request for a cardiovascular outcomes study, which is to be conducted at the earliest. The agency specified that the concerned study has to be underway at the time of submission of the new drug application (NDA) for ETC-1002. Any uncertainty regarding the benefit/risk assessment of ETC-1002 might trigger the need to complete the cardiovascular outcomes study before the candidate can be approved.
Esperion intends to initiate a global long-term safety study on ETC-1002 by 2015 end.
We believe that the FDA’s advice has a serious implication regarding the timing of NDA submission for ETC-1002. Launch of a new study will involve a lot of resources and could take a long time (even years) to complete. Hence, it will substantially delay the submission of an NDA for ETC-1002. If approved, the drug may face a challenge in gaining market share due to late entry into the market.
The Fly On The Wall ( also Marketbeat )
Valeant Pharmaceuticals International ( VRX )10/27/15 RBC Capital Outperform $231.00
not buying now